Difference between revisions of "Crizotinib"
Jump to navigation
Jump to search
| Line 4: | Line 4: | ||
*[[Lung carcinoma with ALK rearrangement]].<ref>{{Cite journal | last1 = Wu | first1 = YL. | last2 = Lu | first2 = S. | last3 = Lu | first3 = Y. | last4 = Zhou | first4 = J. | last5 = Shi | first5 = YK. | last6 = Sriuranpong | first6 = V. | last7 = Ho | first7 = JCM. | last8 = Ong | first8 = CK. | last9 = Tsai | first9 = CM. | title = Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. | journal = J Thorac Oncol | volume = | issue = | pages = | month = Jun | year = 2018 | doi = 10.1016/j.jtho.2018.06.012 | PMID = 29966800 }}</ref> | *[[Lung carcinoma with ALK rearrangement]].<ref>{{Cite journal | last1 = Wu | first1 = YL. | last2 = Lu | first2 = S. | last3 = Lu | first3 = Y. | last4 = Zhou | first4 = J. | last5 = Shi | first5 = YK. | last6 = Sriuranpong | first6 = V. | last7 = Ho | first7 = JCM. | last8 = Ong | first8 = CK. | last9 = Tsai | first9 = CM. | title = Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. | journal = J Thorac Oncol | volume = | issue = | pages = | month = Jun | year = 2018 | doi = 10.1016/j.jtho.2018.06.012 | PMID = 29966800 }}</ref> | ||
*Lung carcinoma with MET amplification.<ref>{{Cite journal | last1 = Forde | first1 = PM. | last2 = Rudin | first2 = CM. | title = Crizotinib in the treatment of non-small-cell lung cancer. | journal = Expert Opin Pharmacother | volume = 13 | issue = 8 | pages = 1195-201 | month = Jun | year = 2012 | doi = 10.1517/14656566.2012.688029 | PMID = 22594847 }}</ref> | *Lung carcinoma with MET amplification.<ref>{{Cite journal | last1 = Forde | first1 = PM. | last2 = Rudin | first2 = CM. | title = Crizotinib in the treatment of non-small-cell lung cancer. | journal = Expert Opin Pharmacother | volume = 13 | issue = 8 | pages = 1195-201 | month = Jun | year = 2012 | doi = 10.1517/14656566.2012.688029 | PMID = 22594847 }}</ref> | ||
Crizotinib has been largely subplanted by a new generation of ALK inhibitors that were designed to cross the blood-brain barrier.<ref name=pmid31331844>{{Cite journal | last1 = Wrona | first1 = A. | title = Management of CNS disease in ALK-positive non-small cell lung cancer: Is whole brain radiotherapy still needed? | journal = Cancer Radiother | volume = 23 | issue = 5 | pages = 432-438 | month = Sep | year = 2019 | doi = 10.1016/j.canrad.2019.03.009 | PMID = 31331844 }}</ref> | |||
==See also== | ==See also== | ||
Revision as of 20:00, 16 October 2019
Crizotinib a drug used to treat lung cancer. Its' trade name is Xalkori (Pfizer).[1] It is an ALK inhibitor.
- Lung cancer with ROS1 rearrangement.[2]
- Lung carcinoma with ALK rearrangement.[3]
- Lung carcinoma with MET amplification.[4]
Crizotinib has been largely subplanted by a new generation of ALK inhibitors that were designed to cross the blood-brain barrier.[5]
See also
References
- ↑ URL: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/crizotinib. Accessed on: November 8, 2018.
- ↑ Shaw, AT.; Ou, SH.; Bang, YJ.; Camidge, DR.; Solomon, BJ.; Salgia, R.; Riely, GJ.; Varella-Garcia, M. et al. (Nov 2014). "Crizotinib in ROS1-rearranged non-small-cell lung cancer.". N Engl J Med 371 (21): 1963-71. doi:10.1056/NEJMoa1406766. PMID 25264305.
- ↑ Wu, YL.; Lu, S.; Lu, Y.; Zhou, J.; Shi, YK.; Sriuranpong, V.; Ho, JCM.; Ong, CK. et al. (Jun 2018). "Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer.". J Thorac Oncol. doi:10.1016/j.jtho.2018.06.012. PMID 29966800.
- ↑ Forde, PM.; Rudin, CM. (Jun 2012). "Crizotinib in the treatment of non-small-cell lung cancer.". Expert Opin Pharmacother 13 (8): 1195-201. doi:10.1517/14656566.2012.688029. PMID 22594847.
- ↑ Wrona, A. (Sep 2019). "Management of CNS disease in ALK-positive non-small cell lung cancer: Is whole brain radiotherapy still needed?". Cancer Radiother 23 (5): 432-438. doi:10.1016/j.canrad.2019.03.009. PMID 31331844.